New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 2, 2013
16:19 EDTREGN, SNYSanofi, Regeneron report positive proof-of-concept data for dupilumab
Sanofi (SNY) and Regeneron Pharmaceuticals (REGN) announced that pooled data from two Phase 1b trials with dupilumab (REGN668/SAR231893), an investigational, high-affinity, subcutaneously administered, fully-human antibody targeting the alpha subunit of the interleukin 4 receptor (IL-4R alpha), were presented at the 71st Annual Meeting of the American Academy of Dermatology (AAD) in Miami.
News For SNY;REGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 7, 2015
08:36 EDTREGNPiper Jaffray conference call is cancelled
Biopharmaceuticals Analyst Schimmer, along with Dr. Diana Do, a leading clinician-scientist who specializes in the treatment of retinal conditions at the University of Nebraska, discuss the current practice dynamics and treatment of wet-AMD (age-related macular degeneration), the recent AAVL Phase 2a dataset and key points of debate and emerging treatment options in wet-AMD on an Analyst/Industry conference call to be held on July 7 at 4:30 pm.
July 6, 2015
16:34 EDTSNYRetrophin closes sale of Priority Review Voucher to Sanofi
Subscribe for More Information
June 26, 2015
05:25 EDTREGNRegeneron reports approval of Eylea by Japan
Subscribe for More Information
June 25, 2015
14:03 EDTSNYSanofi initiated with a Buy at HSBC
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use